Legend Biotech CEO Ying Huang
June 4, 2022 06:43 PM EDTUpdated June 6, 09:11 AM
R&D
China
Cell/Gene Tx

#AS­CO22: Leg­end, J&J say Carvyk­ti holds up past the two-year mark as pair preps for po­ten­tial sec­ond nod

Kyle LaHucik

Senior Reporter

CHICA­GO — The sec­ond BC­MA CAR-T ap­proved, Carvyk­ti, has shown it can stay ef­fec­tive at al­most 28 months of me­di­an fol­low-up, with over­all re­sponse rate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times